Although a family history of myeloid malignancies or immunodeficiency may help in the decision to screen for GATA2 variants, it is important to note that GATA2 de novo variants constitute a significant proportion of cases in some phenotypes such as in children or young adults with MDS (Wlodarski et al., 2016). This evidence concerns the gene GATA2 and Immunodeficiency.